Tibial Tunnel Widening in Anterior Cruciate Ligament (ACL) Reconstruction-Comparing Two Bioscrews
NCT ID: NCT01727739
Last Updated: 2019-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2012-11-30
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specifically the study has the following objectives: 1) To quantify the extent of tibial tunnel enlargement at 3-, 6- and 12-months post ACL reconstruction with autogenous quadrupled hamstring graft; 2) To determine if the incorporation of beta tricalcium phosphate to the bioabsorbable interference screw alters the observed magnitude of tunnel widening; 3) To hypothesize mechanisms for any observed differences between tibial fixation devices; and 4) To correlate tibial tunnel widening with clinical outcome status. It is hypothesized that the PLLA+TCP bioabsorbable interference screw will not be associated with a reduction in tibial tunnel widening around the implant but rather between the implant and articular surface, compared to the PLLA alone screw. It is also hypothesized that there will be no effect of observed tunnel widening on clinical outcomes or graft failure rates.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws
NCT02918734
A Study to Evaluate the Incrediwear Products Immediately After ACL Repair
NCT06668376
Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)
NCT01634711
Anterior Cruciate Ligament Reconstruction Hybrid Remnant Repair
NCT05494073
Obtain Safety and Effectiveness of CT-ACL001, a Regenerative Ligament Using Biological Tissue, in ACLR
NCT07129694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PLLA bioscrew
poly-L-lactic acid bioscrew
Linvatec PLLA
Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
PLLA+TCP bioscrew
poly-l-lactic acid with beta tricalcium phosphate bioscrew
Linvatec PLLA+TCP
Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Linvatec PLLA+TCP
Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
Linvatec PLLA
Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be between 18 and 45 years old
Exclusion Criteria
* Severe chondromalacia or severe meniscal tear
* Previous history of ipsilateral knee joint pathology, surgery, or trauma to that knee
* Unwillingness to be followed for 12 months post-operatively
* History of arthritis (osteoarthritis or rheumatoid)
* Pregnancy
* Psychiatric illness that precludes informed consent
* Unable to speak or read English/French
* Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Panam Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter MacDonald
Research Associate
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter B MacDonald, MD FRCS(C)
Role: PRINCIPAL_INVESTIGATOR
Pan Am Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pan Am Clinic
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2012:059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.